Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 30 | 2023 | 1591 | 7.220 |
Why?
|
Antiviral Agents | 38 | 2023 | 2987 | 6.310 |
Why?
|
Hepatitis C, Chronic | 18 | 2023 | 1031 | 5.120 |
Why?
|
Hepacivirus | 30 | 2023 | 1379 | 5.110 |
Why?
|
Cost-Benefit Analysis | 45 | 2022 | 5391 | 4.320 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2023 | 2214 | 2.560 |
Why?
|
Quality-Adjusted Life Years | 24 | 2021 | 1683 | 2.150 |
Why?
|
Liver Diseases, Alcoholic | 3 | 2023 | 161 | 2.120 |
Why?
|
Liver Neoplasms | 11 | 2023 | 4253 | 2.020 |
Why?
|
Models, Economic | 8 | 2021 | 713 | 1.940 |
Why?
|
Markov Chains | 14 | 2021 | 969 | 1.910 |
Why?
|
Liver Transplantation | 7 | 2019 | 2119 | 1.800 |
Why?
|
Models, Theoretical | 14 | 2019 | 3589 | 1.580 |
Why?
|
Prisoners | 4 | 2019 | 297 | 1.150 |
Why?
|
Health Care Costs | 8 | 2023 | 3209 | 1.060 |
Why?
|
Anus Neoplasms | 4 | 2018 | 332 | 1.050 |
Why?
|
Opioid-Related Disorders | 4 | 2023 | 2065 | 0.940 |
Why?
|
End Stage Liver Disease | 2 | 2019 | 314 | 0.940 |
Why?
|
Mass Screening | 10 | 2021 | 5255 | 0.930 |
Why?
|
Decision Support Techniques | 6 | 2021 | 1956 | 0.850 |
Why?
|
Cost of Illness | 7 | 2023 | 1859 | 0.750 |
Why?
|
Alcohol-Related Disorders | 1 | 2023 | 234 | 0.750 |
Why?
|
Epidemics | 2 | 2023 | 523 | 0.710 |
Why?
|
Disease Transmission, Infectious | 2 | 2015 | 547 | 0.700 |
Why?
|
Papillomavirus Infections | 7 | 2021 | 1587 | 0.690 |
Why?
|
Papillomavirus Vaccines | 4 | 2019 | 491 | 0.680 |
Why?
|
Liver Cirrhosis | 8 | 2023 | 1863 | 0.670 |
Why?
|
Genotype | 9 | 2019 | 12951 | 0.650 |
Why?
|
Costs and Cost Analysis | 5 | 2017 | 1681 | 0.630 |
Why?
|
Online Systems | 1 | 2018 | 184 | 0.620 |
Why?
|
Humans | 118 | 2024 | 744343 | 0.600 |
Why?
|
Hepatitis, Alcoholic | 1 | 2019 | 103 | 0.600 |
Why?
|
Proline | 3 | 2013 | 458 | 0.600 |
Why?
|
Chenodeoxycholic Acid | 1 | 2017 | 34 | 0.590 |
Why?
|
United States | 36 | 2023 | 69872 | 0.560 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3674 | 0.550 |
Why?
|
Waiting Lists | 2 | 2019 | 692 | 0.550 |
Why?
|
Chemoprevention | 1 | 2018 | 319 | 0.550 |
Why?
|
Cholangitis | 1 | 2017 | 108 | 0.540 |
Why?
|
Pandemics | 8 | 2023 | 8388 | 0.540 |
Why?
|
Drugs, Generic | 2 | 2018 | 421 | 0.530 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 1596 | 0.530 |
Why?
|
Homosexuality, Male | 3 | 2017 | 1240 | 0.510 |
Why?
|
Liver Diseases | 2 | 2023 | 1253 | 0.510 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 70 | 0.500 |
Why?
|
Carcinoma in Situ | 2 | 2017 | 806 | 0.490 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.470 |
Why?
|
Hematologic Neoplasms | 2 | 2015 | 1832 | 0.450 |
Why?
|
Cost Savings | 2 | 2020 | 926 | 0.420 |
Why?
|
Mass Vaccination | 1 | 2013 | 105 | 0.420 |
Why?
|
Decision Making | 5 | 2018 | 3887 | 0.410 |
Why?
|
Probability | 2 | 2022 | 2505 | 0.410 |
Why?
|
Gastroenterology | 1 | 2017 | 536 | 0.400 |
Why?
|
Uncertainty | 1 | 2016 | 734 | 0.400 |
Why?
|
Economics, Medical | 2 | 2022 | 113 | 0.390 |
Why?
|
Drug Costs | 2 | 2018 | 1105 | 0.390 |
Why?
|
Prisons | 4 | 2023 | 161 | 0.380 |
Why?
|
Precancerous Conditions | 1 | 2017 | 975 | 0.370 |
Why?
|
Models, Biological | 2 | 2019 | 9583 | 0.370 |
Why?
|
Hepatitis B | 3 | 2020 | 695 | 0.360 |
Why?
|
Prevalence | 10 | 2023 | 15226 | 0.360 |
Why?
|
Risk Assessment | 11 | 2020 | 23338 | 0.360 |
Why?
|
Schools | 2 | 2020 | 1433 | 0.350 |
Why?
|
Benzimidazoles | 1 | 2015 | 850 | 0.350 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2013 | 459 | 0.340 |
Why?
|
Public Health | 5 | 2023 | 2603 | 0.340 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1170 | 0.340 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 3022 | 0.330 |
Why?
|
Health Policy | 3 | 2018 | 2661 | 0.320 |
Why?
|
Spain | 2 | 2019 | 465 | 0.320 |
Why?
|
Viremia | 3 | 2023 | 736 | 0.310 |
Why?
|
Budgets | 3 | 2019 | 229 | 0.300 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 5034 | 0.290 |
Why?
|
Life Expectancy | 3 | 2019 | 1184 | 0.280 |
Why?
|
Incidence | 9 | 2023 | 20947 | 0.280 |
Why?
|
Middle Aged | 36 | 2024 | 213383 | 0.270 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2716 | 0.270 |
Why?
|
Adult | 33 | 2024 | 214055 | 0.270 |
Why?
|
alpha-Fetoproteins | 2 | 2023 | 224 | 0.270 |
Why?
|
Hematologic Tests | 2 | 2023 | 240 | 0.260 |
Why?
|
Female | 43 | 2023 | 380194 | 0.250 |
Why?
|
Male | 36 | 2022 | 350118 | 0.250 |
Why?
|
Treatment Outcome | 14 | 2021 | 63114 | 0.240 |
Why?
|
Moldova | 1 | 2023 | 15 | 0.240 |
Why?
|
Forecasting | 3 | 2022 | 2951 | 0.230 |
Why?
|
Models, Statistical | 5 | 2020 | 5102 | 0.230 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 127 | 0.230 |
Why?
|
Stroke | 2 | 2022 | 9981 | 0.220 |
Why?
|
Mammography | 6 | 2014 | 2476 | 0.210 |
Why?
|
Gastroplasty | 1 | 2024 | 142 | 0.210 |
Why?
|
Basic Reproduction Number | 1 | 2022 | 31 | 0.210 |
Why?
|
Georgia (Republic) | 1 | 2021 | 41 | 0.210 |
Why?
|
Influenza, Human | 1 | 2013 | 1479 | 0.210 |
Why?
|
Alcohol Drinking | 3 | 2022 | 3966 | 0.210 |
Why?
|
Computer Simulation | 5 | 2020 | 6196 | 0.200 |
Why?
|
HIV Infections | 5 | 2023 | 16718 | 0.200 |
Why?
|
Aged | 23 | 2022 | 163280 | 0.190 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2022 | 2020 | 0.190 |
Why?
|
Substance Abuse, Intravenous | 2 | 2023 | 525 | 0.190 |
Why?
|
Microbiological Techniques | 1 | 2021 | 102 | 0.190 |
Why?
|
Reproducibility of Results | 4 | 2020 | 19905 | 0.190 |
Why?
|
Naloxone | 1 | 2023 | 367 | 0.190 |
Why?
|
Brugada Syndrome | 1 | 2021 | 97 | 0.180 |
Why?
|
Adenosine Monophosphate | 1 | 2022 | 275 | 0.180 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 87 | 0.180 |
Why?
|
Alanine | 1 | 2022 | 572 | 0.180 |
Why?
|
Disease Progression | 4 | 2017 | 13284 | 0.170 |
Why?
|
Sentinel Surveillance | 1 | 2021 | 281 | 0.170 |
Why?
|
Indians, North American | 1 | 2023 | 355 | 0.170 |
Why?
|
Logistic Models | 4 | 2014 | 13408 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9239 | 0.170 |
Why?
|
Administration, Oral | 2 | 2017 | 3913 | 0.170 |
Why?
|
Tissue Donors | 2 | 2018 | 2240 | 0.160 |
Why?
|
Hyperthyroidism | 1 | 2021 | 295 | 0.160 |
Why?
|
Pennsylvania | 3 | 2016 | 613 | 0.160 |
Why?
|
Systems Analysis | 1 | 2019 | 172 | 0.160 |
Why?
|
Contact Tracing | 1 | 2020 | 273 | 0.160 |
Why?
|
Pakistan | 1 | 2019 | 295 | 0.160 |
Why?
|
Quarantine | 1 | 2020 | 170 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
Electric Countershock | 1 | 2021 | 534 | 0.160 |
Why?
|
Bariatric Surgery | 2 | 2019 | 952 | 0.160 |
Why?
|
Papillomaviridae | 3 | 2021 | 1119 | 0.160 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5137 | 0.160 |
Why?
|
France | 1 | 2019 | 517 | 0.150 |
Why?
|
Comparative Effectiveness Research | 2 | 2021 | 681 | 0.150 |
Why?
|
India | 3 | 2021 | 2197 | 0.150 |
Why?
|
Population Surveillance | 2 | 2020 | 2616 | 0.150 |
Why?
|
Operations Research | 1 | 2017 | 23 | 0.150 |
Why?
|
Genital Diseases, Male | 1 | 2017 | 84 | 0.150 |
Why?
|
Cohort Studies | 6 | 2018 | 40561 | 0.150 |
Why?
|
Italy | 1 | 2019 | 832 | 0.150 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39050 | 0.150 |
Why?
|
Germany | 1 | 2019 | 862 | 0.150 |
Why?
|
Policy | 1 | 2020 | 508 | 0.140 |
Why?
|
Carbamates | 1 | 2018 | 196 | 0.140 |
Why?
|
Pharyngeal Diseases | 1 | 2017 | 133 | 0.140 |
Why?
|
Ethanol | 1 | 2023 | 1342 | 0.140 |
Why?
|
Vaccination | 2 | 2019 | 3278 | 0.140 |
Why?
|
Medicaid | 3 | 2019 | 2736 | 0.140 |
Why?
|
Transportation of Patients | 2 | 2015 | 185 | 0.140 |
Why?
|
Dengue | 1 | 2019 | 256 | 0.140 |
Why?
|
Genital Diseases, Female | 1 | 2017 | 197 | 0.140 |
Why?
|
Diagnostic Tests, Routine | 1 | 2022 | 783 | 0.140 |
Why?
|
Health Priorities | 1 | 2019 | 380 | 0.140 |
Why?
|
Obesity, Morbid | 2 | 2017 | 1213 | 0.140 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2021 | 454 | 0.140 |
Why?
|
Aged, 80 and over | 10 | 2020 | 57776 | 0.140 |
Why?
|
Interferon-alpha | 3 | 2015 | 895 | 0.130 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2015 | 65 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.130 |
Why?
|
Japan | 1 | 2020 | 1360 | 0.130 |
Why?
|
Fibrosis | 1 | 2022 | 2029 | 0.130 |
Why?
|
World Health Organization | 2 | 2018 | 1318 | 0.130 |
Why?
|
Breast Neoplasms | 7 | 2019 | 20822 | 0.130 |
Why?
|
Mouth Diseases | 1 | 2017 | 241 | 0.130 |
Why?
|
Thyroidectomy | 1 | 2021 | 879 | 0.130 |
Why?
|
Regional Health Planning | 1 | 2015 | 97 | 0.130 |
Why?
|
Time | 1 | 2017 | 542 | 0.130 |
Why?
|
Elasticity Imaging Techniques | 1 | 2020 | 388 | 0.130 |
Why?
|
Nutrition Surveys | 2 | 2019 | 1660 | 0.130 |
Why?
|
Decision Making, Computer-Assisted | 2 | 2012 | 150 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.120 |
Why?
|
Time Factors | 8 | 2021 | 40075 | 0.120 |
Why?
|
Sensitivity and Specificity | 8 | 2023 | 14722 | 0.120 |
Why?
|
Gadolinium DTPA | 3 | 2023 | 836 | 0.120 |
Why?
|
Thyroid Nodule | 1 | 2021 | 750 | 0.110 |
Why?
|
Guideline Adherence | 2 | 2021 | 2266 | 0.110 |
Why?
|
Alcoholism | 1 | 2023 | 1906 | 0.110 |
Why?
|
Suicide | 1 | 2023 | 1477 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5078 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 9959 | 0.100 |
Why?
|
Folic Acid | 1 | 2019 | 1300 | 0.100 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1440 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2749 | 0.100 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15540 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1641 | 0.100 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2015 | 397 | 0.100 |
Why?
|
Quality of Life | 5 | 2024 | 12804 | 0.100 |
Why?
|
Hospital Costs | 1 | 2017 | 985 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2019 | 880 | 0.090 |
Why?
|
Immunization Programs | 1 | 2013 | 260 | 0.090 |
Why?
|
Health Expenditures | 1 | 2023 | 2348 | 0.090 |
Why?
|
Neoplasms, Second Primary | 1 | 2018 | 1061 | 0.090 |
Why?
|
Hemorrhage | 1 | 2022 | 3461 | 0.090 |
Why?
|
Mental Health | 2 | 2023 | 3019 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1796 | 0.090 |
Why?
|
Trauma Centers | 1 | 2015 | 890 | 0.090 |
Why?
|
HIV | 1 | 2017 | 1604 | 0.090 |
Why?
|
Young Adult | 5 | 2019 | 56430 | 0.090 |
Why?
|
Risk Factors | 10 | 2023 | 72290 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4933 | 0.080 |
Why?
|
Triage | 1 | 2015 | 976 | 0.080 |
Why?
|
Gastric Bypass | 1 | 2017 | 812 | 0.080 |
Why?
|
Preoperative Care | 1 | 2017 | 2250 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2023 | 77449 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2021 | 2282 | 0.080 |
Why?
|
Disease Management | 1 | 2018 | 2459 | 0.070 |
Why?
|
Acute Disease | 1 | 2018 | 7149 | 0.070 |
Why?
|
Prospective Studies | 4 | 2021 | 53288 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3086 | 0.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 949 | 0.070 |
Why?
|
Anti-Retroviral Agents | 1 | 2016 | 1715 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1101 | 0.070 |
Why?
|
SEER Program | 3 | 2018 | 1508 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3297 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10252 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1378 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18370 | 0.070 |
Why?
|
Primary Health Care | 2 | 2021 | 4558 | 0.070 |
Why?
|
Life Style | 1 | 2017 | 3835 | 0.060 |
Why?
|
Medicare | 2 | 2022 | 6566 | 0.060 |
Why?
|
ROC Curve | 2 | 2009 | 3527 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.060 |
Why?
|
Registries | 4 | 2018 | 8089 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7474 | 0.060 |
Why?
|
Washington | 2 | 2015 | 313 | 0.060 |
Why?
|
Weight Loss | 3 | 2024 | 2622 | 0.060 |
Why?
|
Contrast Media | 3 | 2023 | 5300 | 0.060 |
Why?
|
Regression Analysis | 2 | 2014 | 6459 | 0.060 |
Why?
|
Adolescent | 7 | 2018 | 85781 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4397 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7279 | 0.060 |
Why?
|
Breast | 1 | 2012 | 1969 | 0.060 |
Why?
|
Pattern Recognition, Automated | 1 | 2009 | 1005 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2019 | 3712 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11366 | 0.060 |
Why?
|
Calibration | 2 | 2019 | 816 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3760 | 0.060 |
Why?
|
Chronic Disease | 1 | 2018 | 9146 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1184 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Critical Illness | 1 | 2015 | 2670 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3528 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2023 | 401 | 0.050 |
Why?
|
Malaysia | 1 | 2021 | 92 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29063 | 0.050 |
Why?
|
Ribavirin | 2 | 2013 | 395 | 0.050 |
Why?
|
Societies | 1 | 2021 | 104 | 0.050 |
Why?
|
Organizations, Nonprofit | 1 | 2021 | 104 | 0.050 |
Why?
|
Algorithms | 3 | 2017 | 13881 | 0.050 |
Why?
|
Software | 1 | 2015 | 4443 | 0.050 |
Why?
|
Ohio | 1 | 2020 | 337 | 0.040 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2019 | 40 | 0.040 |
Why?
|
HIV-1 | 1 | 2017 | 6939 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 569 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2022 | 2309 | 0.040 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 128 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5319 | 0.040 |
Why?
|
Georgia | 1 | 2018 | 186 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 551 | 0.040 |
Why?
|
New York | 1 | 2020 | 886 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 35421 | 0.040 |
Why?
|
Vaginal Neoplasms | 1 | 2018 | 106 | 0.040 |
Why?
|
Criminal Law | 1 | 2018 | 96 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 262 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2013 | 1182 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2018 | 513 | 0.040 |
Why?
|
Penile Neoplasms | 1 | 2018 | 160 | 0.040 |
Why?
|
Homosexuality | 1 | 2017 | 262 | 0.040 |
Why?
|
Vitamin B Complex | 1 | 2019 | 288 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25043 | 0.040 |
Why?
|
National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2015 | 10 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 4042 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 500 | 0.030 |
Why?
|
Risk | 2 | 2020 | 9687 | 0.030 |
Why?
|
Universities | 1 | 2021 | 956 | 0.030 |
Why?
|
Vulvar Neoplasms | 1 | 2018 | 272 | 0.030 |
Why?
|
Football | 1 | 2021 | 460 | 0.030 |
Why?
|
Bed Occupancy | 1 | 2015 | 41 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2021 | 855 | 0.030 |
Why?
|
Homocysteine | 1 | 2019 | 647 | 0.030 |
Why?
|
Body Mass Index | 3 | 2017 | 12720 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2023 | 1248 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.030 |
Why?
|
Social Class | 1 | 2022 | 1999 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 87 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2013 | 6622 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15076 | 0.030 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 477 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15165 | 0.030 |
Why?
|
Drug Combinations | 1 | 2018 | 1959 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6489 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1405 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2017 | 492 | 0.030 |
Why?
|
Sex Distribution | 1 | 2017 | 2297 | 0.030 |
Why?
|
Patient Care Team | 1 | 2023 | 2531 | 0.030 |
Why?
|
Income | 1 | 2020 | 1913 | 0.020 |
Why?
|
Recovery of Function | 1 | 2021 | 2925 | 0.020 |
Why?
|
Reoperation | 1 | 2021 | 4201 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2214 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1339 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 12745 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2494 | 0.020 |
Why?
|
Developing Countries | 1 | 2020 | 2815 | 0.020 |
Why?
|
Survivors | 1 | 2018 | 2291 | 0.020 |
Why?
|
Electrocardiography | 1 | 2021 | 6442 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2017 | 2057 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 719 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2737 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.020 |
Why?
|
Mortality | 1 | 2015 | 2864 | 0.010 |
Why?
|
Depression | 1 | 2023 | 7766 | 0.010 |
Why?
|
Patient Discharge | 1 | 2015 | 3313 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1917 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11031 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13989 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12026 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12959 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2010 | 8949 | 0.010 |
Why?
|